Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 18

1.

Dapagliflozin: a review on efficacy, clinical effectiveness and safety.

Paisley AN, Yadav R, Younis N, Rao-Balakrishna P, Soran H.

Expert Opin Investig Drugs. 2013 Jan;22(1):131-40. doi: 10.1517/13543784.2013.740009. Epub 2012 Nov 6. Review. Erratum in: Expert Opin Investig Drugs. 2013 Jul;22(7):939. Paisley, Angela J [corrected to Paisley, Angela N].

PMID:
23127205
2.

Pituitary apoplexy masquerading as bacterial meningitis.

Paisley AN, Syed AA.

CMAJ. 2012 Nov 6;184(16):1812. doi: 10.1503/cmaj.120174. Epub 2012 Jun 4. No abstract available.

3.

Real time presence of a microbiologist in a multidisciplinary diabetes foot clinic.

Paisley AN, Kalavalapalli S, Subudhi CP, Chadwick PR, Chadwick PJ, Young B.

Diabetes Res Clin Pract. 2012 Apr;96(1):e1-3. doi: 10.1016/j.diabres.2011.11.024. Epub 2012 Jan 5.

PMID:
22226078
4.

Changes in arterial stiffness but not carotid intimal thickness in acromegaly.

Paisley AN, Banerjee M, Rezai M, Schofield RE, Balakrishnannair S, Herbert A, Lawrance JA, Trainer PJ, Cruickshank JK.

J Clin Endocrinol Metab. 2011 May;96(5):1486-92. doi: 10.1210/jc.2010-2225. Epub 2011 Feb 23.

PMID:
21346071
5.

Investigating secondary hyperhidrosis.

Paisley AN, Buckler HM.

BMJ. 2010 Sep 9;341:c4475. doi: 10.1136/bmj.c4475. No abstract available.

PMID:
20829299
6.

Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.

Paisley AN, Savage MW, Wiles PG.

Diabet Med. 2009 Sep;26(9):935-8. doi: 10.1111/j.1464-5491.2009.02789.x.

PMID:
19719716
7.

A subnormal peak cortisol response to stimulation testing does not predict a subnormal cortisol production rate.

Paisley AN, Rowles SV, Brandon D, Trainer PJ.

J Clin Endocrinol Metab. 2009 May;94(5):1757-60. doi: 10.1210/jc.2008-2392. Epub 2009 Feb 24.

PMID:
19240150
8.

Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly.

Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM.

J Clin Endocrinol Metab. 2009 Apr;94(4):1111-7. doi: 10.1210/jc.2008-0948. Epub 2009 Jan 27.

PMID:
19174501
9.

Treatment of acromegaly improves quality of life, measured by AcroQol.

Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L, Shalet SM, Trainer PJ.

Clin Endocrinol (Oxf). 2007 Sep;67(3):358-62. Epub 2007 Jun 6.

PMID:
17555502
10.

Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.

Paisley AN, Roberts ME, Trainer PJ.

Clin Endocrinol (Oxf). 2007 May;66(5):723-6. Epub 2007 Mar 27.

PMID:
17388793
11.

Pegvisomant interference in GH assays results in underestimation of GH levels.

Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ.

Eur J Endocrinol. 2007 Mar;156(3):315-9.

12.

Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.

Paisley AN, O'Callaghan CJ, Lewandowski KC, Parkinson C, Roberts ME, Drake WM, Monson JP, Trainer PJ, Randeva HS.

J Clin Endocrinol Metab. 2006 Nov;91(11):4635-40. Epub 2006 Aug 22.

PMID:
16926249
13.

Recent developments in the therapy of acromegaly.

Paisley AN, Trainer PJ.

Expert Opin Investig Drugs. 2006 Mar;15(3):251-6. Review.

PMID:
16503762
14.

Treatment of pituitary tumors: pegvisomant.

Paisley AN, Drake WM.

Endocrine. 2005 Oct;28(1):111-4. Review.

PMID:
16311417
15.
16.

The place of pegvisomant in the acromegaly treatment algorithm.

Paisley AN, Trainer PJ, Drake WM.

Growth Horm IGF Res. 2004 Jun;14 Suppl A:S101-6. Review.

PMID:
15135788
17.

Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.

Paisley AN, Trainer P, Drake W.

Expert Opin Biol Ther. 2004 Mar;4(3):421-5. Review.

PMID:
15006735
18.

Medical treatment in acromegaly.

Paisley AN, Trainer PJ.

Curr Opin Pharmacol. 2003 Dec;3(6):672-7. Review.

PMID:
14644022
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk